A new vaccine against coronavirus BCD-250 developed by biotech company Biocad(a participant of Made in Russia project) has already passed preclinical tests and received approval for clinical trials, which may start as early as this year, the company's press service told the project.

"The start of clinical trials is planned for 2021-2022. Volunteer recruitment for the clinical trials will start shortly," Biocad said.

The company added that recruitment of volunteers will start soon. They will be vaccinated and observed in two medical centers in St. Petersburg.

Previously, the Russian Ministry of Health issued Biocad permission to conduct Phase I and Phase II trials of the recombinant vector vaccine. The trials are expected to be completed by December 31, 2026, with 360 participants.

Made in Russia // Made in Russia

Author: Karina Kamalova